Drug profile · INN
imetelstat sodium
RYTELO
imetelstat sodium (RYTELO) is a telomerase reverse transcriptase inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — imetelstat sodium
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
imetelstat sodium (RYTELO) is a telomerase reverse transcriptase inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Telomerase reverse transcriptase inhibitor
Primary target: Telomerase reverse transcriptase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is imetelstat sodium?
imetelstat sodium (RYTELO) is a telomerase reverse transcriptase inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for imetelstat sodium?
RYTELO is a marketed brand name for imetelstat sodium. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of imetelstat sodium?
imetelstat sodium has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.